Trials / Completed
CompletedNCT05452798
A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,054 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to retrospectively describe and assess clinical and demographical characteristics, treatment patterns in a real-world (RW) setting of patients with HR+/HER2- (hormone receptor positive/human epidermal growth factor receptor 2 negative) locally advanced or metastatic breast cancer receiving palbociclib in combination treatment
Conditions
Timeline
- Start date
- 2022-02-01
- Primary completion
- 2022-08-01
- Completion
- 2022-08-01
- First posted
- 2022-07-11
- Last updated
- 2024-03-01
- Results posted
- 2024-03-01
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT05452798. Inclusion in this directory is not an endorsement.